Related references
Note: Only part of the references are listed.
Letter
Medicine, General & Internal
Sophie Caillard et al.
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Rheumatology
Chen Shen et al.
Summary: The study found that the mRNA-1273 and BNT162b2 vaccines are effective in individuals taking immunosuppressants. However, these individuals are still at higher risk of SARS-CoV-2 infection and COVID-19 hospitalization compared to the general vaccinated population. Booster doses are effective and crucial for individuals on immunosuppressants.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Michael Bonelli et al.
Summary: This study found that an additional booster vaccination is effective and safe for non-seroconverted patients after receiving conventional COVID-19 vaccination. Both vector and mRNA vaccines have comparable efficacy in enhancing humoral and cellular immune response, which is particularly important for immunosuppressed patients.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Editorial Material
Medicine, General & Internal
Carlos del Rio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Immunology
Rekha R. Rapaka et al.
Summary: COVID-19 vaccine trials offer valuable insights into the safety and efficacy of vaccines, but comparing efficacy results is not straightforward. Factors related to trial context and design must be considered when making such comparisons.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Public, Environmental & Occupational Health
Jill M. Ferdinands et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2022)
Article
Rheumatology
Amir Bieber et al.
Summary: This study used data from Clalit Health Services, which covers more than half of the population in Israel, to investigate the association between COVID-19 vaccination and outcomes in patients with autoimmune rheumatic diseases (ARD). The results showed that both the BNT162b2 mRNA COVID-19 vaccine and the booster dose were associated with better COVID-19 outcomes in patients with ARD.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Nadia Emi Aikawa et al.
Summary: This study aimed to determine the immunogenicity of the third dose of CoronaVac vaccine in patients with autoimmune rheumatic diseases (ARD) and identify factors associated with impaired response. The results showed a significant increase in antibody positivity rates after the third dose of the vaccine in ARD patients. However, certain medications may reduce immune response. These findings are important for guiding vaccination strategies in patients with ARD.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Virology
Santenna Chenchula et al.
Summary: This article discusses the importance and durability of COVID-19 vaccine boosters in the context of the COVID-19 Omicron variant. A systematic review of 27 published studies has been conducted to evaluate the effectiveness of COVID-19 vaccine boosters against the Omicron variant.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Review
Rheumatology
Rebecca Grainger et al.
Summary: This review summarizes the current knowledge on SARS-CoV-2 infection, COVID-19 prevention and treatment in people with rheumatic disease. It suggests that rheumatic disease is associated with a slightly higher risk of SARS-CoV-2 infection, but outcomes of COVID-19 are influenced by comorbidities and specific disease states or treatments. Further research is needed to address the specific considerations for people with rheumatic disease.
NATURE REVIEWS RHEUMATOLOGY
(2022)
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After administering the fourth dose of BNT162b2 vaccine to individuals aged 60 years and older during the period when the omicron variant was predominant, Israel observed lower rates of confirmed SARS-CoV-2 infection and severe Covid-19 compared to those who received only three doses. The protection against severe illness remained consistent, while the protection against confirmed infection decreased over time.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Ori Magen et al.
Summary: The use of a fourth dose of BNT162b2 vaccine in Israel starting on January 3, 2022, has shown significant reductions in infection rate, symptomatic infection, hospitalization, and Covid-19-related deaths by February 18.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Rheumatology
Nadia E. Aikawa et al.
Summary: This study assesses the immunogenicity of a fourth dose of mRNA SARS-CoV-2 vaccine in autoimmune rheumatic disease patients who had a poor or non-response to the third dose of an inactivated vaccine. The results show that most patients had a significant increase in antibody levels after the fourth dose, but a portion of patients still did not have an adequate antibody response. The use of specific drugs, such as rituximab and prednisone, may impair the antibody response.
Article
Medicine, General & Internal
Adam S. Lauring et al.
Summary: mRNA vaccines were highly effective in preventing covid-19 associated hospital admissions related to the alpha, delta, and omicron variants. Three vaccine doses were required for protection against omicron, while two doses provided protection against delta and alpha variants. Omicron variant showed lower disease severity compared to delta variant but still resulted in morbidity and mortality. Vaccinated patients had lower disease severity than unvaccinated patients for all the variants.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Multidisciplinary Sciences
Tal Patalon et al.
Summary: In this retrospective study, the authors demonstrate a significant waning of mRNA vaccine effectiveness against the Omicron variant of SARS-CoV-2 infection within a few months after administration of the third dose of the BioNTech/Pfizer BNT162b2 vaccine.
NATURE COMMUNICATIONS
(2022)
Article
Rheumatology
Jose J. Hernandez-Munoz et al.
Summary: The study estimated a prevalence of 2 cases of RA per 1,000 beneficiaries in Puerto Rico in 2016, with a higher prevalence among females compared to males. Rheumatologists and a combination of specialties had the highest median number of dispensed DMARDs, at 14 each. Sensitivity analysis showed that changing the RA case definition could affect the estimated prevalence.
ARTHRITIS CARE & RESEARCH
(2021)
Article
Rheumatology
Rene Cordtz et al.
Summary: The study found that patients with inflammatory rheumatic diseases (IRD) were more likely to be hospitalized with COVID-19, while treatment with specific DMARDs did not affect the risk of hospitalization for RA patients, but could increase the risk of severe outcomes.
Article
Rheumatology
Anja Strangfeld et al.
Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
David Simon et al.
Summary: Immune response against SARS-CoV-2 is delayed and reduced in patients with immune-mediated inflammatory diseases, regardless of treatment.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Rheumatology
Bryant R. England et al.
Summary: In a cohort study of US Department of Veterans Affairs, it was found that patients with RA have a higher risk and severity of COVID-19 compared to those without RA, indicating the importance of prioritizing RA patients for COVID-19 prevention and management strategies.
ARTHRITIS & RHEUMATOLOGY
(2021)
Article
Rheumatology
Victoria Furer et al.
Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Yolanda Braun-Moscovici et al.
Summary: The vast majority of patients with inflammatory rheumatic diseases developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
